Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam (NASDAQ: BEAT) announced a partnership with HeartNexus to offer a 24/7 cardiology reader service that delivers cardiologist-level ECG interpretation for patients outside traditional care settings.
Patients will capture a 30-second recording with HeartBeam’s credit-card-sized, cable-free device; its patented 3D technology synthesizes a 12-lead ECG that is securely transmitted to board-certified cardiologists for immediate review and feedback to the patient or clinician.
The cardiology reader service is planned to launch after the company’s anticipated FDA clearance of its 12-lead ECG synthesis software, which HeartBeam continues to expect in Q4 2025. Future ecosystem enhancements may include AI wellness, community features, and wearable integration.
HeartBeam (NASDAQ: BEAT) announced promising results from a new study demonstrating the effectiveness of their deep learning algorithms in detecting cardiac arrhythmias. The study, presented at HRX Live 2025, showed that HeartBeam's AI algorithms achieved 94.5% accuracy when used with their credit card-sized 3D ECG system, comparable to the 95.5% accuracy with standard 12-lead ECGs.
The study involved 201 patients and evaluated the detection of atrial fibrillation, atrial flutter, and sinus rhythm. The algorithms, developed from over 10,000 standard 12-lead ECGs, will be used to support future FDA submissions to enhance HeartBeam's product offerings.
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care, announced its participation in three major industry conferences in September 2025. CEO Robert Eno and CFO Timothy Cruickshank will attend the MDB Investor Summit (September 4), HRX Live 2025 (September 4-6), and H.C. Wainwright Global Investment Conference (September 8-10).
The company will showcase its FDA-cleared HeartBeam System, a cable-free, credit card-sized device that collects 3D ECG signals for arrhythmia assessment. At HRX Live, Dr. Joshua Lampert from Mount Sinai Heart will present new data comparing HeartBeam's AI algorithm performance for detecting atrial flutter and fibrillation.
HeartBeam (NASDAQ: BEAT) reported Q2 2025 financial results and provided updates on its commercial readiness plans. The company's pivotal VALID-ECG study demonstrated 93.4% overall diagnostic agreement for its 12-lead ECG synthesis software. HeartBeam continues productive FDA discussions, expecting 510(k) clearance by year-end.
Financial highlights include $5.1 million in cash and equivalents, with Q2 net loss of $5.0 million. R&D expenses increased to $3.3 million from $2.8 million year-over-year, while G&A expenses decreased to $1.7 million from $2.2 million.
The company expanded its business development team and received two industry recognitions, including the Innovation Award in Remote Cardiac Diagnostics. HeartBeam's patent portfolio now includes 21 issued patents worldwide.
HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care solutions, has scheduled its Q2 2025 earnings conference call for August 13, 2025, at 4:30 p.m. Eastern time. The call will be led by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss second quarter results and provide updates on regulatory initiatives and commercial activities.
The earnings release will be issued before the call, which will include a presentation accessible through the company's investor relations website. Participants can join via phone using U.S. dial-in 1-844-826-3035 or international dial-in 1-412-317-5195 with conference code 10201583. A webcast will also be available, and a replay will be accessible until November 13, 2025.
HeartBeam (NASDAQ: BEAT) has been awarded the Innovation Award in Remote Cardiac Diagnostics at the 2025 Medical Device Network Excellence Awards for its groundbreaking FDA-cleared ECG technology. The company's proprietary technology captures heart electrical signals in 3D non-coplanar directions and synthesizes them into a 12-lead ECG using a credit card-sized, cable-free device.
The technology enables clinical-grade diagnostics for arrhythmia assessment outside traditional healthcare settings, allowing patients to record symptoms as they occur. HeartBeam's 12-lead ECG synthesis software is currently under FDA review, with commercialization planned upon clearance. The company has previously received multiple industry recognitions, including the Pinnacle Healthcare Award and MedTech Breakthrough Award.
- Strategic collaboration with AccurKardia to enhance arrhythmia assessment capabilities
- Raised $11.5M through public offering in February 2025
- Added two new US patents, now owning 20 issued patents globally
- Cash position of $8.2M as of March 31, 2025
HeartBeam (NASDAQ: BEAT) has secured two new U.S. patents, strengthening its intellectual property portfolio in cardiac monitoring technology. The first patent protects their credit card-sized, cable-free 3D ECG device with chest and finger electrodes that capture high-fidelity electrical signals in three non-coplanar directions. The second patent covers their rhythm analysis algorithm for distinguishing between various heart rhythms using continuous signal input, designed for integration with wearable devices.
The company's 12-lead ECG synthesis software is currently under FDA review, supported by data from the VALID-ECG pivotal study presented at the Heart Rhythm Society conference in April 2025. HeartBeam now holds 20 issued patents worldwide, with 2 allowed patents and 32 pending patents, positioning itself as a leader in cardiac monitoring innovation.
HeartBeam (NASDAQ: BEAT) has appointed CEO Robert Eno to its Board of Directors, expanding from eight to nine members. Eno, who joined as President in January 2023 and became CEO in October 2024, brings over 30 years of medical technology industry experience. The company received FDA clearance for its 3D ECG technology in December 2024 and submitted an FDA application for its 12-lead ECG synthesis software in January 2025.
HeartBeam's technology captures heart electrical signals in 3 non-coplanar directions and synthesizes them into a 12-lead ECG. The company has initiated an Early Access Program to gather feedback on clinical workflow and establish early adopters. Prior to HeartBeam, Eno served as CEO of Preview Medical and held leadership roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular.